Test Price
2,800 AED✅ Home Collection Available
GRID2 Gene Spinocerebellar Ataxia Type 18 (Autosomal Recessive) Genetic Test in UAE | 2,800 AED | DHA Licensed
Executive Summary & Core Metrics
Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139).
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
- Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation with a DHA‑licensed Consultant Medical Genetics.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The GRID2 Gene Spinocerebellar Ataxia Type 18 NGS Test detects pathogenic variants in the GRID2 gene with unrivaled depth and accuracy, enabling definitive molecular diagnosis of this autosomal recessive neurodegenerative disorder.
| Feature | Our GRID2 NGS Test | Closest Alternative (Single‑Gene Sanger Sequencing) |
|---|---|---|
| Methodology | Next‑Generation Sequencing (NGS) with full gene coverage and CNV analysis | Sanger sequencing of selected exons only |
| Diagnostic Yield | >98% for GRID2 variants, including deep intronic and structural variants | ~80%, limited to known common mutations |
| Turnaround Time | 3–4 Weeks | 4–6 Weeks |
| Pre‑Test Requirement | Includes mandatory genetic counselling session and pedigree charting | Often omitted; counselling not integrated |
Physician Insight & Safety Protocols
Medication Safety Advisory
Important Notice
Do not discontinue prescribed medication without consulting your doctor. Abrupt cessation of anti‑epileptics, muscle relaxants, or any neurological drug may provoke severe withdrawal symptoms, seizure relapse, or status epilepticus.
Safety Exclusion Criteria & Emergency Red Flags
- Exclusion criteria for home collection: Active febrile illness, ongoing acute neurological decompensation, inability to provide informed consent, or patient under 18 years without a legal guardian as mandated by Federal Law No. 2 of 2019 concerning the Use of ICT in Health Fields.
- Pregnancy: Testing is generally not recommended unless clinically justified after genetic counselling, as results may have implications for reproductive planning.
- Emergency Red Flags – Seek immediate medical attention (call 998 or visit ER) if you experience: sudden, severe worsening of gait instability, frequent falls, swallowing difficulties with choking, or sudden onset of respiratory distress.
- Prior to specimen collection, a comprehensive clinical history and formal genetic counselling session to construct a detailed pedigree chart are mandatory.
Patient FAQ & Clinical Guidance
1. What is the GRID2 spinocerebellar ataxia type 18 NGS test, and who should consider it?
This NGS-based genetic test provides definitive molecular confirmation of biallelic GRID2 mutations, helping neurologists and geneticists confirm autosomal recessive spinocerebellar ataxia type 18 in patients with progressive cerebellar ataxia and a relevant family history.
2. How is the test performed and what sample is needed?
A simple blood sample, extracted DNA, or a single drop of blood on an FTA card is collected by a certified phlebotomist during an 8 AM – 11 PM home visit, then transported under strict cold‑chain conditions for NGS analysis.
3. What do the results mean and will I receive clinical support?
A positive result identifies disease‑causing GRID2 variants, enabling precise carrier testing for family members and prenatal options; a negative result, however, does not exclude other hereditary ataxias, requiring further neurological evaluation.
For post‑clinical guidance, WhatsApp +971 54 548 8731 to schedule a tele‑consultation.
UAE Regulatory & Data Privacy Adherence
DNA Labs UAE strictly adheres to the Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical testing and patient consent protocols comply with Federal Decree-Law No. 4 of 2016 on Medical Liability. This test is processed under ISO 9001:2015 quality management (Cert: INT/EGQ/2509DA/3139).
Clinical & Logistical Metadata
| Test Name | GRID2 Gene Spinocerebellar Ataxia Type 18 (Autosomal Recessive) NGS Genetic Test |
| Price (AED) | 2,800 |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood, Extracted DNA, or FTA Card Specimen |
| Methodology Used | Next-Generation Sequencing (NGS) with full gene coverage and CNV analysis |
| ICD-10-CM Code | G11.8 (Other hereditary ataxias) |
| LOINC Code | 81247-9 (Neurology Genetic Disease Sequencing Panel) |
| DHA Facility License & Laboratory Address | DHA License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians